Merger and Acquisition Scenario
Par Pharmaceutical Companies, Inc. (PRX) and Progenics Pharmaceuticals, Inc. (PGNX)
| Date: | Sep 06, 2008 |
|---|---|
| Format: | HTML |
| Price: | $250.00 |
Abstract
Revere Data's Merger & Acquisition Scenario Report offers independent, objective and insightful analysis into a hypothetical combination of Par Pharmaceutical Companies, Inc. (PRX) with Progenics Pharmaceuticals, Inc. (PGNX) . The Revere report begins by identifying Par Pharmaceutical Companies, Inc. products that are either complementary or overlapping to Progenics Pharmaceuticals, Inc. products. Par Pharmaceutical Companies, Inc. suppliers are then displayed alongside Progenics Pharmaceuticals, Inc. suppliers, with overlapping suppliers to both firms highlighted. Dependent suppliers to both companies are also displayed, including the percentage of dependent revenue if known. Top Par Pharmaceutical Companies, Inc. customers and top Progenics Pharmaceuticals, Inc. customers, including overlapping customers, are also shown. The Revere report then includes key business relationship data in the area of strategic partnerships for each company. Additional content and features include Lines of Business Summaries, Product Summaries, Individual Par Pharmaceutical Companies, Inc. Product Line and Progenics Pharmaceuticals, Inc. Product Line Details, Par Pharmaceutical Companies, Inc. Earnings and Progenics Pharmaceuticals, Inc. Earnings Summaries, and pro forma financial statements. Revere Data Merger & Acquisition Scenario Reports are an essential source of competitive insight into an array of potential merger, acquisition, takeover, consolidation, rollup or other combination scenarios, with particular focus in the healthcare, biotechnology, information technology, finance and media sectors. Revere's extensive databases on key business relationships, product lines, focused sectors, and financial performance indicators provide a rich and integrated information source for investment banking, corporate finance, C-level executives, management consultants, marketing, and business intelligence professionals who want actionable answers and ideas in seconds.
Report Contents
- Summary
- Lines of Business Summary
- Product Summary
- Overlap & Complementary Sectors
- Sample Products in Similar Lines of Business
- Sample Products in Complementary Lines of Business
- Business Relationship Summary
- Top Key Suppliers
- Top Key Customers
- Key Financial Summary
- Individual Company Summary
- Focused Sector
- Revenue/Earnings Summary
- Business Description
- Product Summary
- Product Details
- Relationship Details
- Key Competitors
- Dependent Suppliers
- Key Customers
- Key Partners
- Financials
- Income Statement
- Balance Sheet
- Cash Flow
Companies Mentioned in the Report
- Progenics Pharmaceuticals, Inc. (PGNX) - Overview - Reports
- Par Pharmaceutical Companies, Inc. (PRX) - Overview - Reports
More Information:
Learn more about Merger and Acquisition Scenario Report.
Don't see the Scenario report you want? Request Merger and Acquisition Scenario Report »
Download Fact Sheet Merger and Acquisition Scenario (PDF)
Related Reports:
- Merger and Acquisition Scenario for Bristol Myers Squibb Co. (BMY) and Par Pharmaceutical Companies, Inc. (PRX)
- Merger and Acquisition Scenario for Theravance, Inc. (THRX) and Par Pharmaceutical Companies, Inc. (PRX)
- Merger and Acquisition Scenario for Warner Chilcott Plc (WCRX) and Par Pharmaceutical Companies, Inc. (PRX)
- Merger and Acquisition Scenario for Eisai Co., Ltd (ADR) (ESALY) and Par Pharmaceutical Companies, Inc. (PRX)